Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Major contract win

16 May 2014 12:25

RNS Number : 3595H
Venn Life Sciences Holdings PLC
16 May 2014
 



Venn Life Sciences Holdings Plc

("Venn" or the "Company")

 

Major contract win

 

Venn Life Sciences Signs Master Service Agreement for Multi-Country Study

Value is in excess of €3m covering 8 countries in Europe & North America over 18 months

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the securing of a multi-country multi-million euro clinical trials management agreement with a major European biotechnology company.

 

This multi-site agreement will run for over a year and a half, covering seven European countries as well as a number of US sites and is valued in excess of €3m. The clinical trial management programme is for an orphan drug in a rare acute disease area and is proceeding this month.

 

Over the past year Venn has increased its geographic footprint in Europe with new offices in the UK and Germany. Business development has been focused on key growth areas of drug and device development and on winning similar studies across Europe, with a solid pipeline of work for 2014 and 2015 now secured. Studies in rare diseases have increased significantly in recent years and Venn has invested in ensuring they have the critical multi-site agile service capabilities essential to conduct and manage trials efficiently in this sector.

 

Commenting, Venn CEO, Tony Richardson, said:

"We are hearing from many of our clients - in the key pharmaceutical, biotechnology and medical device sectors - of a growing need for a much more agile multi-country clinical trial management capability, especially in the still complex greater European region. Venn has invested heavily in 2013 in preparing the business for a step change in the size and complexity of contracts undertaken. This contract win, and our current pipeline, represent a significant endorsement of our investment strategy since IPO. We have now moved our business focus from small single country projects to larger multicentred projects and we expect to cement this progress with additional project wins in the coming months."

 

Enquiries:

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla McGuinness, Marketing Manager

Tel: +33 (0)1 30 82 67 07

Zeus Capital (Nominated Adviser and Broker)

Ross Andrews/Andrew Jones (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727

Walbrook PR Ltd

Tel: 020 7933 8787 or venn@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - innoVenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTBBGDUSDBBGSL
Date   Source Headline
28th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSAppointment of Non Executive Director
13th Sep 20167:00 amRNSDirectorate Change
24th Aug 20167:00 amRNSNotice of Results
3rd Aug 20167:00 amRNSContract wins
30th Jun 201612:18 pmRNSResult of AGM
30th Jun 20167:00 amRNSAGM Statement
20th Jun 20164:24 pmRNSShareholder notification
10th Jun 201611:05 amRNSPosting of Annual Report and Notice of AGM
10th May 20167:00 amRNSFinal Results
24th Mar 20167:00 amRNSYear End Update
18th Jan 20168:00 amRNSEnterprise Securities Market Notice
13th Jan 20167:00 amRNSESM Schedule 1 update
13th Jan 20167:00 amRNSESM Appendix to Schedule 1 update
12th Jan 20167:00 amRNSContracts worth EUR 3.4m signed with US Biotech
8th Jan 20162:03 pmRNSHolding(s) in Company
8th Jan 20167:01 amRNSTrading update
8th Jan 20167:00 amRNSDirectorate Change
11th Dec 20157:00 amRNSChange of Adviser
11th Dec 20157:00 amRNSESM Pre-Admission Announcement
11th Dec 20157:00 amRNSAppendix to Schedule 1 announcement
3rd Nov 20157:00 amRNSGrant of Share Option & Total Voting Rights
23rd Oct 20157:00 amRNSContract for over EUR1m with French Biotech
19th Oct 20157:00 amRNSAppointment of Director
19th Oct 20157:00 amRNSCompletion of the Acquisition of Kinesis Pharma BV
9th Oct 201511:38 amRNSResult of General Meeting & Update on Acquisition
22nd Sep 20157:01 amRNSHalf Yearly Report
22nd Sep 20157:00 amRNSProposed acquisition & Placing
24th Aug 20152:00 pmRNSAppointment of Co-Broker
21st Aug 20157:00 amRNSNotice of Results
13th Aug 20157:00 amRNSTrading update
30th Jun 201511:39 amRNSResult of AGM
30th Jun 20157:00 amRNSAGM Statement
15th Jun 20157:00 amRNSAppointment of Chief Financial Officer
10th Jun 20153:46 pmRNSEUR 2m contract with leading European biotech
28th May 201510:14 amRNSPosting of Annual Report & Notice of AGM
22nd May 20157:00 amRNSFinal Results
20th May 20153:29 pmRNSHolding(s) in Company
20th May 20157:00 amRNSNew services from Innovenn
12th May 20157:01 amRNSDirectorate Change
8th Apr 20159:06 amRNSHolding(s) in Company
8th Apr 20159:05 amRNSHolding(s) in Company
7th Apr 20152:39 pmRNSHolding(s) in Company
7th Apr 201511:17 amRNSHolding(s) in Company
2nd Apr 20152:00 pmRNSInvestor teach-in
2nd Apr 20157:00 amRNSInnoVenn expands products and first sales in US
1st Apr 201512:14 pmRNSResult of General Meeting
30th Mar 20157:00 amRNSContracts for EUR4.1m with US Biotech client
13th Mar 20154:45 pmRNSPlacing to raise £2 million
6th Mar 20157:00 amRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.